"VistaGen - PH94B, PH10 and AV-101 - are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients" VistaGen's ceo
"During the year, we prioritised development of our anti-fibrotic candidate, NXP002, and are developing an inhaled formulation. Our preparations for first clinical exposure are underway. We are looking at all options for deriving value from this product globally" So two months ago they announced "preparations for clinical work". Surely these "preparations" must be completed now and clinical trials begun.
NFX is becoming like an worn coat. More often than not a red worn coat. Come on NFX, give us something of substance to hang our hats on as winter is coming and that coat is starting to get uncomfortably thin.
Why it's blue at the top of the page beats me . Nice to see, but selling at 3.62 and buying at 3.72 does not give a mid price of 3.75. Although covid effected many companies it did seem that many took advantage of the situation and some didn't ATB
So basically you little "chat" with Martin covered exactly the same ground that we had in the rns. Little if any work done, with the weather used as an excuse this time rather than covid.
As time marches on and we are a couple of weeks away from October I would really like to know how much cash they have atm, and what the monthly cash burn is. Would like to hear more of the "income stream ", and what we have actually recieved since the last financials. Just get that feeling that things are tight and precarious at this low sp. And yes I know that they said they have enough til year end, but no sensible company waits til the cash box is empty before raising finance.